Premium
Seroreactivity against MAGE‐A and LAGE‐1 proteins in melanoma patients
Author(s) -
Usener D.,
Gerhardt A.,
Schadendorf D.,
Eichmüller S.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2003.05410.x
Subject(s) - antigen , serology , antibody , immunogenicity , biology , melanoma , immunology , recombinant dna , gene , cdna library , complementary dna , gene expression , microbiology and biotechnology , virology , cancer research , genetics
Summary Background Cancer‐testis antigens exemplify a growing number of tumour antigens which are expressed in a variety of malignancies, but not in normal tissues other than germ cells, primarily those of the testis. Objectives To investigate the humoral response to known cancer‐testis antigens in melanoma patients. Methods We used phage clones coding for seven different melanoma antigens MAGE‐A or LAGE‐1A proteins. These clones were isolated using the newly developed DNA hybridization analysis of recombinantly expressed cDNA libraries (HYREX) approach. HYREX combines the advantage of a nonradioactive library screening method with the possibility of subsequently analysing the serological response to the recombinant proteins. We isolated clones coding for MAGE‐A1, ‐A3, ‐A4b, ‐A6, ‐A9 and ‐A12, as well as LAGE‐1A. Additionally, we correlated gene expression and seroreactivity. Results Between 13% and 27% of sera ( n = 15) were reactive against individual tumour antigens. We found the presence of specific antibodies was, with only two exceptions, generally correlated with mRNA expression of the antigen within cell lines derived from the same patient. While cross‐reactivity of patients' IgG might play a role in these cases, antibodies from patients' sera were able to distinguish even the closely related MAGE‐A3 and ‐A6. In general, the mRNA expression frequency was higher than the detected IgG responses. Conclusions Antibody recognition of specific tumour antigens by patients' sera may be used for evaluating the possible immunogenicity of new antigens; serological tests could be used for tumour monitoring purposes.